AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin complex treatments, has announced its participation in the upcoming Aegis Capital Corp. 2025 Virtual Conference. The company's President and CEO, Rob Bancroft, will deliver a corporate overview presentation on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. AEON's focus is on developing treatments for multiple therapeutic indications using their botulinum toxin complex technology.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti a base di complessi di tossina botulinica, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Aegis Capital Corp. 2025. Il Presidente e CEO della società, Rob Bancroft, terrà una presentazione aziendale mercoledì 21 maggio alle 7:00 a.m. PT / 10:00 a.m. ET. AEON si concentra sullo sviluppo di terapie per diverse indicazioni terapeutiche utilizzando la loro tecnologia basata sul complesso di tossina botulinica.
AEON Biopharma (NYSE: AEON), una compañía biofarmacéutica en etapa clínica que desarrolla tratamientos con complejos de toxina botulínica, ha anunciado su participación en la próxima Conferencia Virtual de Aegis Capital Corp. 2025. El presidente y CEO de la empresa, Rob Bancroft, ofrecerá una presentación corporativa el miércoles 21 de mayo a las 7:00 a.m. PT / 10:00 a.m. ET. AEON se enfoca en desarrollar tratamientos para múltiples indicaciones terapéuticas utilizando su tecnología de complejos de toxina botulínica.
AEON Biopharma (NYSE: AEON)는 보툴리눔 독소 복합체 치료제를 개발하는 임상 단계의 바이오제약 회사로, 다가오는 Aegis Capital Corp. 2025 가상 컨퍼런스에 참여할 예정임을 발표했습니다. 회사의 사장 겸 CEO인 Rob Bancroft는 5월 21일 수요일 오전 7시 PT / 오전 10시 ET에 회사 개요 발표를 진행할 예정입니다. AEON은 보툴리눔 독소 복합체 기술을 활용하여 다양한 치료 적응증에 대한 치료법 개발에 주력하고 있습니다.
AEON Biopharma (NYSE : AEON), une société biopharmaceutique en phase clinique développant des traitements à base de complexes de toxine botulique, a annoncé sa participation à la prochaine Conférence Virtuelle Aegis Capital Corp. 2025. Le président-directeur général de l'entreprise, Rob Bancroft, présentera un aperçu de la société le mercredi 21 mai à 7h00 PT / 10h00 ET. AEON se concentre sur le développement de traitements pour plusieurs indications thérapeutiques en utilisant leur technologie de complexes de toxine botulique.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Behandlungen mit Botulinumtoxin-Komplexen entwickelt, hat seine Teilnahme an der bevorstehenden Aegis Capital Corp. 2025 Virtuellen Konferenz angekündigt. Der Präsident und CEO des Unternehmens, Rob Bancroft, wird am Mittwoch, den 21. Mai um 7:00 Uhr PT / 10:00 Uhr ET eine Unternehmenspräsentation halten. AEON konzentriert sich auf die Entwicklung von Behandlungen für verschiedene therapeutische Indikationen unter Verwendung ihrer Botulinumtoxin-Komplex-Technologie.
- None.
- None.
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET.
Please register here to attend the conference on Wednesday, May 21st.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
When is AEON Biopharma (AEON) presenting at the Aegis Capital Corp. Virtual Conference 2025?
Who will be presenting for AEON Biopharma at the Aegis Conference 2025?
What is AEON Biopharma's (AEON) main focus as a company?
What stock exchange is AEON Biopharma listed on?
